Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma

Inclusion Criteria: * 1）Aged 18 to 75 years. * 2）Newly diagnosed glioblastoma consistent with the World Health Organization (WHO) Classification of Tumours of the Central Nervous System, 5th edition. * 3）Epidermal growth factor receptor (EGFR)-positive status confirmed by immunohistochemistry (defined as brown-yellow staining in \>10% of tumor cells). * 4）Partial surgical resection with radiographically measurable residual tumor. * 5）Karnofsky Performance Status (KPS) score ≥ 50% (with KPS decline attributable to the tumor). * 6）Adequate renal function, defined as serum creatinine ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance \> 60 mL/min. * 7）Adequate hepatic function, defined as total bilirubin ≤ 1.5 times the ULN and serum transaminases ≤ 3 times the ULN. * 8）Adequate hematologic function, defined as a white blood cell count ≥ 3,000/μL or an absolute neutrophil count (ANC) ≥ 1,500/μL, platelet count ≥ 100,000/μL, and hemoglobin ≥ 10 g/dL. * 9）An interval of 2 to 6 weeks between surgical resection and the initiation of radiotherapy (RT). Exclusion Criteria: * 1）EGFR-negative status. * 2）Prior treatment with chemotherapy, anti-EGFR therapy, or radiotherapy; or a history of other malignancies within the past 5 years. * 3）Presence of severe comorbidities or active infections, or persistent vomiting that may interfere with the oral administration of temozolomide (TMZ).